Interpreting the clinical utility of a pharmacogenomic marker based on observational association studies

Michael Sorich, Michael Coory

    Research output: Contribution to journalArticle

    8 Citations (Scopus)

    Abstract

    It is increasingly recognized that the clinical utility of a pharmacogenomic marker is a fundamental characteristic influencing the likelihood of successful clinical translation. Although appropriately designed and executed randomized controlled trials generally provide the most valid evidence for the clinical utility of a pharmacogenomic marker, such evidence may not always be available. Observational pharmacogenomic association studies are a common form of evidence available, but the assessment of clinical utility based on such evidence is often not straightforward. This paper aims to provide insight into this issue using a range of illustrative examples.

    Original languageEnglish
    Pages (from-to)1-5
    Number of pages5
    JournalPHARMACOGENOMICS JOURNAL
    Volume14
    Issue number1
    DOIs
    Publication statusPublished - 2014

    Fingerprint Dive into the research topics of 'Interpreting the clinical utility of a pharmacogenomic marker based on observational association studies'. Together they form a unique fingerprint.

  • Cite this